Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fadraciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cyclacel To Present Fadraciclib Data At EORTC-NCI-AACR Symposium
    Cyclacel To Present Fadraciclib Data At EORTC-NCI-AACR Symposium

    09 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//en/news-release/2024/10/09/2960613/10564/en/Cyclacel-Pharmaceuticals-to-Present-New-Clinical-Data-From-Phase-2-Study-of-Oral-Fadraciclib-at-the-2024-EORTC-NCI-AACR-Symposium.html

    GLOBENEWSWIRE
    09 Oct 2024
    Share Share
    Cyclacel Completes Enrollment In Phase 2 Study Cohort
    Cyclacel Completes Enrollment In Phase 2 Study Cohort

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2953054/10564/en/Cyclacel-Pharmaceuticals-Announces-Completion-of-Enrollment-in-the-Biomarker-Enriched-Patient-Cohort-of-Its-Phase-2-Study.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Cyclacel To Participate In H.C. Wainwright Conference
    Cyclacel To Participate In H.C. Wainwright Conference

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940616/10564/en/Cyclacel-Pharmaceuticals-Announces-Participation-at-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Cyclacel: Fadraciclib Efficacy In Colorectal Cancer Models At ASCO 2024
    Cyclacel: Fadraciclib Efficacy In Colorectal Cancer Models At ASCO 2024

    04 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/04/2892966/10564/en/Cyclacel-s-Fadraciclib-Demonstrates-Efficacy-in-Patient-Derived-Colorectal-Cancer-Models-at-the-2024-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    04 Jun 2024
    Share Share
    Cyclacel's Fadraciclib Precision Cancer Med Potential At ASCO 2024
    Cyclacel's Fadraciclib Precision Cancer Med Potential At ASCO 2024

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892187/10564/en/Cyclacel-Pharmaceuticals-Reports-New-Clinical-Data-at-2024-ASCO-Annual-Meeting-Highlighting-Oral-Fadraciclib-s-Potential-as-a-Precision-Medicine-for-Cancer.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Cyclacel to Present New Clinical Data at ASCO Meeting Highlighting Fadraciclib
    Cyclacel to Present New Clinical Data at ASCO Meeting Highlighting Fadraciclib

    01 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/01/2855230/10564/en/Cyclacel-Pharmaceuticals-to-Present-New-Clinical-Data-at-2024-ASCO-Annual-Meeting-Highlighting-Fadraciclib-s-Potential-as-a-Precision-Medicine-for-Cancer.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share